Who is sponsoring NCT00323011?

NCT00323011 is sponsored by University of Southern California.

What condition does NCT00323011 study?

NCT00323011 studies Colorectal Cancer.

What drugs are being tested in NCT00323011?

Interventions: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab.

What is the status of NCT00323011?

NCT00323011 is currently TERMINATED.

Last reviewed 2014-05-20 · How we verify

A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

NCT00323011 Phase 2 TERMINATED

This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a problem in patients receiving cancer drugs. Studies have shown that up to 17% of patients receiving cancer drugs experienced blood-clotting problems. One purpose of this study is to find if the drug combination of irinotecan, 5-fluorouracil (5-FU), bevacizumab and leucovorin (LV) affect blood-clotting factors. A second purpose of this study is to find out what effects the drug dalteparin has on clotting factors in the blood in patients receiving the drug combination of irinotecan, 5-FU, bevacizumab and LV. It is hoped that adding dalteparin to chemotherapy may benefit patients with colorectal cancer by preventing blood clots

Details

Lead sponsor	University of Southern California
Phase	Phase 2
Status	TERMINATED
Enrolment	5
Start date	2006-05
Completion	2007-11

Conditions

Colorectal Cancer

Interventions

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab

Countries

United States